Thermo Fisher Completes $8.875 Billion Acquisition of Clario Holdings
Thermo Fisher said it closed its acquisition of Clario Holdings, a provider of endpoint data solutions for clinical trials, for $8.875 billion in cash plus possible earn-out and other payments. The company expects the deal to contribute $0.45 of adjusted earnings per share in the first year after close, with details to come on its first-quarter earnings call.
Key points
- Purchase price: $8.875 billion in cash at closing, plus $125 million due in January 2027 and up to $400 million in earn-out payments tied to 2026 and 2027 performance
- Expected contribution: $0.45 adjusted EPS in the first year after close
- Synergy target: approximately $175 million of adjusted operating income by year 5 after close
- Clario will be part of the Laboratory Products and Biopharma Services segment
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 24, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.